PremiumSMMT

SMMT: trial data, analysts, and insiders are buying

Despite encouraging clinical data and a stock decline, three insiders with impressive resumes are buying company shares worth millions of dollars.

By the SpyStocks desk · 2mo ago · 3 min read

The rest of this story is for members

The rest is for members

The story continues: the full timeline, the transaction ranges, and the names the forms carry.

Premium comes through the Telegram channel. Already have a code? Sign in to activate it.

Telegram@TheAmericanDream5

Real-time buys, sweeps, and trading halts from the desk. Free to join.